On target: genetically modified cells show promise in targeted immunotherapy for advanced blood cancers.

摘要

Targeted cellular immunotherapy is showing early promise in patients with advanced blood cancers, and many investigators are enthusiastic about the possibilities offered by the new technology.Results of research from several centers investigating the technique of using genetically engineered T cells to fight leukemia were highlighted during the annual meeting of the American Society of Hematology (ASH), held in New Orleans, Louisiana, in December 2013."I think this approach is an entirely new paradigm for leukemia therapy, and maybe cancer in general," says David Porter, MD, director of blood and marrow transplantation at the University of Pennsylvania (Penn) Abramson Cancer Center, which pioneered the method along with the Children's Hospital of Philadelphia.